Background. In lung transplant recipients (LTRs), the measurement of human cytomegalovirus (HCMV) load dynamics in the local environment of the lung allograft may offer distinct advantages over their assessment in the peripheral blood compartment.
Improved clinical management of human cytomegalovirus (HCMV) disease in lung transplant recipients (LTRs) requires early and accurate detection of HCMV infection. Logistic and sensitivity issues restrict the diagnostic utility of the histological detection of HCMV inclusions in transbronchial biopsy samples, the historical reference standard for detection in LTRs. The use of polymerase chain reaction (PCR) analysis to provide quantitative assessments of HCMV load in plasma samples has led to improvements in both diagnostic sensitivity and specificity. Accordingly, the clinical use of PCR for measuring plasma HCMV DNA is now well estab-lished for a number of different types of solid-organ transplantation, including lung transplantation [1, 2] .
Although the routine use of antiviral prophylaxis after lung transplantation has decreased fulminant HCMVdisease syndromes, as many as 40% of LTRs will be susceptible to HCMV reactivation [3] . Given this tendency of HCMV to selectively target the lung allograft after transplantation, the measurement of HCMV dynamics in the local environment of the lung compartment may offer distinct advantages over the routine measurement of HCMV DNA levels in the peripheral blood compartment [4] . To gain a better understanding of HCMV dynamics in the lung allograft, we performed paired quantitative PCR assays for HCMV in both bronchoalveolar lavage (BAL) and plasma samples from a cohort of LTRs who were followed prospectively after transplantation. We hypothesized that the HCMV "signal"-that is, the level of measured HCMV DNA-would be significantly higher in the BAL compartment, compared with that in blood, and would better predict episodes of histopathologically proven HCMV infection, as well as provide a much improved measure of subclinical virus reactivation within the lung allograft that may be used to better explore the "indirect" effects of HCMV after lung transplantation.
PATIENTS, MATERIALS, AND METHODS

Patients.
Between January 2000 and January 2001, 43 consecutive patients undergoing lung transplantation were considered for inclusion in the present study and were followed longitudinally. One patient who died 5 days posttransplantation, from acute allograft dysfunction related to early graft ischemiareperfusion injury, had not had HCMV load measured and, thus, was excluded from the study analysis.
All LTRs received standard triple-therapy immunosuppression consisting of prednisolone (initially 1 mg/kg/day and titrating to 15 mg/day by 6 months), azathioprine (2 mg/kg/day), and cyclosporine A (maintaining trough levels between 300 and 450 mg/L). Ganciclovir prophylaxis was given to at-risk patients (donor or recipient seropositive for HCMV) at a dosage of 5 mg/ kg intravenously (iv) twice daily for 2 weeks, followed by 5 mg/ kg 3 times per week for an additional 6 weeks. Primary HCMV mismatches (donor positive/recipient negative) also received HCMV hyperimmune gammaglobulin on days 1, 2, 3, 7, 14, 21, 28, and 35 posttransplantation.
All patients had regular surveillance bronchoscopies with transbronchial biopsy sampling of the lung allograft at 2 weeks and 1, 2, 3, 6, 9, and 12 months posttransplantation, and a minority of patients underwent additional bronchoscopies because of clinical deterioration. Acute vascular rejection was assessed using standardized criteria [5] . Episodes of acute rejection (grade A2 or higher) were treated with 3 daily pulses of highdose methylprednisolone. The histological diagnosis of HCMV infection in the lung allograft was made by the detection, in transbronchial biopsy samples, of HCMV inclusion bodies on hematoxylin-eosin stain, with confirmation by use of a biclonal mouse anti-cytomegalovirus immunohistochemical antibody stain (Dakocytomation). In our experience, detection of HCMV inclusion bodies is not uncommon in relatively asymptomatic LTRs at the time of surveillance bronchoscopy; thus, we have avoided using the clinical definition "HCMV pneumonitis" [6] in the present report. When detected histologically in the lung, HCMV infection was treated with a repeat 2-week course of ganciclovir (5 mg/kg twice daily), irrespective of the presence of clinical symptoms and signs of pulmonary disease. The present study was approved by the Alfred Hospital ethics committee.
Samples. BAL samples were collected, pooled, and processed as described elsewhere [7] . At the time of bronchoscopy, paired peripheral blood samples (10 mL) were collected in EDTA tubes. Plasma was separated from whole blood after centrifugation at 1500 g for 10 min and was stored at Ϫ80ЊC until processed.
Quantification of HCMV load. HCMV load was measured in the plasma and BAL samples by use of the semiautomated COBAS Amplicor HCMV monitor test (Roche Diagnostic Systems), according to the manufacturer's instructions and as described elsewhere [8] . Paired measurements were obtained from both the supernatant and cell-pellet fractions of the BAL samples. PCR amplification, hybridization, and colorimetric detection are fully automated with the COBAS Amplicor workstation. HCMV load in plasma samples was recorded as copies per milliliter, whereas HCMV load in BAL samples was recorded as either copies per milliliter of BAL supernatant or copies per milliliter of BAL cell pellet. The lower and upper limits of the assay are 400 and 100,000 copies/mL, respectively. Statistical analysis. Numerical data are expressed as the arithmetic . Comparisons of PCR-detected HCMV mean ‫ע‬ SEM load in the BAL and plasma samples were performed using Spearman's rank correlation coefficient and the McNemar test. Between-group comparisons of HCMV load were performed using the unpaired t test. The correlation between HCMV load and histological detection of HCMV was examined using likelihood ratios. Variables predictive for histologically proven HCMV infection were expressed in tables and analyzed using Fisher's 2 ϫ 2 exact test for categorical data, and results were expressed as odds ratios (95% confidence intervals). Statistical significance was defined as . Statistical analysis was performed using the SAS P ! .05 software package (version 6.12; SAS Institute).
RESULTS
Demographic data.
Data for 42 LTRs were available for analysis. Data for 18 of these LTRs were limited to the first 3 months posttransplantation, because subsequent follow-up was at a distant center, whereas 24 LTRs had follow-up locally and were studied for a total of 12 months posttransplantation. One local patient died of multiorgan failure, at 7 months posttransplantation, after an episode of septicemia. LTRs included 19 men and 23 women whose ages were within the range 18-64 years (mean, 43 years). Twenty-six bilateral and 16 single lung transplantations were performed for a range of conditions, including emphysema ( ), cystic fibrosis ( ), and a number of rarer diseases n p 20 n p 15 ( ). With regard to HCMV serostatus, 7 patients were at n p 7 risk for primary HCMV infection. Donor (D) and recipient (R) HCMV serostatus profiles were as follows:
n p 7 n p 7 Of the 248 bronchoscopies performed, PCR analysis for HCMV DNA was performed on 217 of the BAL samples. A total of 192 plasma samples, collected within 3 days of the bronchoscopies, were analyzed for HCMV DNA. Of the total number of samples, 182 plasma and BAL samples were collected simultaneously (i.e., paired).
HCMV DNA in BAL samples: supernatant versus cells. Measurement of HCMV load in both the cellular and super- (table 1) .
In 38 samples (23.2%), HCMV DNA was detected in both BAL cells and supernatant, whereas HCMV DNA was not detected in either compartment in 119 samples (72.6%). For 5 of 6 BAL samples in which HCMV DNA was detected in the cells but not the supernatant, the absolute value of the virus load measured was in the lowest 15th percentile for all positive samples-that is, was at the lower end of the detection threshold of the PCR assay. For the 38 samples in which HCMV DNA was detected in both BAL cells and supernatant, a strong correlation was found between the levels of HCMV DNA measured in both compartments (Spearman ; ; figure r p 0.61 P ! .0001 1). Because a similar correlation had been observed in a previous analysis of plasma samples [8] , the unit's protocol subsequently changed to measuring HCMV DNA in only the supernatant fraction of the BAL samples, since the methodology was simpler and faster.
HCMV load in BAL and plasma samples. Simultaneous measurement of HCMV load in BAL (cells and/or supernatant) and plasma samples was possible for 182 paired samples (n p 41 patients). The presence in plasma of inhibitors to PCR precluded the measurement of plasma HCMV DNA in 10 samples. Analysis of the remaining 172 paired samples was undertaken (table 1) .
For 14 (8.1%) of the 172 paired samples ( patients), n p 10 HCMV DNA was detected in both the BAL and plasma samples. Of these 10 LTRs with concordantly detectable HCMV DNA in both the plasma and BAL samples, all were considered to be at risk for HCMV infection because of their donor/recipient HCMV serostatus profile (6 (table  2) . During the first 2 months posttransplantation, 27% of BAL samples were positive for the detection of HCMV, despite the routine use of ganciclovir prophylaxis among at-risk patients during this period. After cessation of routine ganciclovir prophylaxis at 2 months posttransplantation, the mean HCMV load measured in BAL samples was seen to increase among the at-risk patients ( copies/mL vs. cop-1117 ‫ע‬ 863 19,580 ‫ע‬ 3481 ies/mL; ). P ! .0001 Seventeen patients had persistent HCMV infection, as defined by the detection of HCMV DNA in BAL samples on 11 occasion. Three patients had recurrent HCMV infection, as defined by the detection of HCMV DNA in BAL samples on 2 different occasions separated by at least 1 BAL sample testing negative for HCMV DNA.
HCMV DNAemia in BAL and plasma samples: histologically proven HCMV infection.
Histological evidence of HCMV infection was detected in 8 patients on 9 occasions, at the time of surveillance bronchoscopy. At the time of diagnosis, ). Compared with the histopathological di-P ! .001 agnosis of HCMV infection, the sensitivity and specificity of HCMV DNA being detected in the BAL samples during the period of study were 100% and 75%, respectively, and the positive and negative likelihood ratios were 4 and 0, respectively (table 3). Detection of plasma HCMV by PCR, during the same time period, had a sensitivity and specificity of 71% and 94%, respectively, and positive and negative likelihood ratios of 12 and 0.3, respectively.
The mean level of HCMV DNA in the BAL samples from the LTRs with histologically proven HCMV infection was higher than that in the BAL samples from those LTRs in whom HCMV DNA was not detected ( copies/mL vs. 19,460 ‫ע‬ 4917 5873 ‫ע‬ copies/mL, respectively;
) and was still signifi-1543 P ! .0001 cantly higher when the low-risk patients (HCMV serostatus profile D Ϫ /R Ϫ ; ) were excluded from the analysis (vs. n p 7 copies/mL; . P ! .0001 A significant number of paired samples were positive for the detection of HCMV DNA in the BAL sample (23%), although histological evidence of HCMV infection was absent. To improve the diagnostic utility of quantitative analysis of HCMV in BAL samples, a higher threshold of HCMV load was applied and tested for relevance. The threshold was arbitrarily set as 2 SD above the mean BAL virus load in LTRs without histologically proven HCMV infection and was calculated as 46,000 copies/mL. The applicability of using a threshold virus load for BAL samples in the diagnosis of histologically proven HCMV infection was confirmed by the receiver operating characteristic curve for the test ( figure 3 ). When measured, all episodes of histologically proven HCMV infection were associated with levels of HCMV in BAL samples of 146,000 copies/mL. Applied to all samples, the higher threshold of HCMV in the BAL samples had a significantly improved diagnostic sensitivity and specificity, compared with other measurements of HCMV DNAemia (table 3) .
Univariate analysis of risk factors for histologically proven HCMV infection. . All episodes occurred during the first 100 days posttransplantation, and all 8 patients first developed HCMV pneumonitis within 4 weeks of the cessation of routine ganciclovir prophylaxis. For the 24 patients who had extended follow-up locally, no histological evidence of HCMV infection was detected after the first 100 days. For 7 patients, analysis of BAL HCMV load was performed before the histological detection of HCMV pneumonitis. In 6 of these 7 LTRs, HCMV DNA was positively detected at a point before the histological diagnosis; however, no identifiable cutoff value could be identified that would beneficially guide preemptive antiviral treatment (figure 2). For only 2 patients, HCMV DNA was detected in the plasma samples before the histological diagnosis. Table 4 shows the results of the univariate analysis of putative risk factors for histologically proven HCMV infection. The detection of HCMV DNA in the BAL samples conferred an increased risk for the development of histologically proven HCMV infection, particularly if the presence of HCMV DNA was persistent or detected early after lung transplantation. HCMV DNAemia at any point posttransplantation also was associated with HCMV disease in the lung allograft.
HCMV and acute rejection. During the first 3 months posttransplantation, 21 patients had acute rejection (grade A2 or higher) detected at the time of routine surveillance bronchoscopy and required treatment with iv methylprednisolone. Thirteen LTRs had persistent acute rejection (11 episode of grade A2 or higher), and 9 patients had late acute rejection (detected after the first 3 months posttransplantation). A statistically significant association was found between treated late acute rejection (grade A2 or higher 13 months posttransplantation) and both detection of HCMV DNA in BAL fluid during the first 60 days posttransplantation ( ) and the histo-P p .03 logical presence of HCMV in the lung allograft ( ). P p .05
DISCUSSION
In the present cohort study, we investigated the dynamics of HCMV replication, particularly in the lung allograft compartment of LTRs and in relation to the histological detection of HCMV infection in the lung allograft. The major finding in our prospective study of 42 LTRs is that high levels of HCMV DNA in BAL samples (above the threshold value of 46,000 copies/mL) are a better predictor of the presence of histologically proven HCMV infection, compared with detection of HCMV DNA in plasma samples. In those patients with histologically proven HCMV infection, HCMV DNA levels were universally detected in the BAL samples and were of significant magnitude, whereas HCMV DNA levels were generally lower in the plasma samples and even may have been concurrently absent. In addition, during the period of study, HCMV DNA was detected at some point in the BAL samples from 57% of all LTRs and in the plasma samples from 25% of all LTRs, a trend that has been described elsewhere for LTRs [9] . Hence, the detection of HCMV DNA in the BAL samples, compared with detection in the plasma samples, was better correlated with the detection of HCMV inclusions in the lung allograft and may offer insights into the indirect effects that HCMV may have on the lung allograft [10] .
The major disadvantage of using qualitative PCR to diagnose HCMV-specific diseases is that the mere detection of HCMV DNA in BAL samples at any given time point is insufficient to predict biopsy-proven HCMV infection, given the low specificity (76%) and poor positive predictive value of detection. Intuitively, higher virus loads are more likely to be associated with more-severe HCMV disease in LTRs, suggesting that the use of threshold levels of BAL HCMV load may offer advantages over the use of qualitative PCR to predict HCMV disease [11] . In the present study, we applied an HCMV-load threshold, described previously by Riise et al. [12] , that was defined as a virus load 2 SD above the mean virus load of all those LTRs without histological evidence of HCMV infection (for this cohort, 46,000 copies/mL BAL of supernatant). Since this threshold is defined by both the patient cohort studied and the PCR methodology used to detect HCMV DNA, its level will most likely vary between centers. The use of a threshold level to predict histologically proven HCMV infection improved diagnostic efficacy, with a sensitivity and specificity of 100% and 95%, respectively. Although not formally analyzed in the present study, we speculate that a high BAL HCMV load (164,000 copies/mL) not only predicts the presence of HCMV inclusions in the lung allograft but also is more likely to be associated with specific symptomatic disease syndromes, such as HCMV pneumonitis [9] .
The detection of HCMV DNA in the BAL samples, irrespective of whether HCMV inclusions were seen in the lung allograft early after transplantation, suggests that ganciclovir prophylaxis did not completely suppress HCMV replication. At this stage, however, we have no clear understanding of a threshold value for HCMV DNAemia that could be used to beneficially guide preemptive antiviral therapy. Conversely, if HCMV DNA is not detected in BAL samples, then LTRs will be unlikely to have histologically detectable HCMV inclusions and, in addition, unlikely to develop HCMV inclusions within the following month. Of importance, on 10 (5%) of 208 occasions, a BAL HCMV load 146,000 copies/mL was measured but was not associated with histologically proven HCMV infection. We speculate that these episodes may represent subclinical HCMV disease that may have indirect long-term effects on the lung allograft [10] . The fact that many LTRs had low levels of HCMV DNA detected in BAL samples but did not have histological evidence of HCMV infection supports the concept of a threshold level of HCMV load above which detection in the allograft becomes probable. Those LTRs with histologically proven HCMV infection had mean HCMV loads in both the BAL ( ) P ! .0001 and plasma ( ) fractions that were higher than in those P ! .001 without disease, a finding that has been described elsewhere for other solid-organ transplant recipients [13] .
Although the presence of HCMV DNA in blood has been crudely associated with the presence of HCMV inclusions in the lung allograft [8, 1] , the inadequacies of plasma HCMV DNA being used as a diagnostic tool were highlighted by the results for 2 patients who had histological evidence of HCMV infection in the absence of concurrent detection of HCMV DNA in plasma. For these patients, the histological finding of HCMV inclusions occurred shortly after cessation of ganciclovir prophylaxis and was detected at routine surveillance bronchoscopy of otherwise asymptomatic LTRs. The use of a combined PCR analysis of HCMV in plasma and BAL samples, to guide treatment strategies, has been advocated in previous studies of LTRs [14] ; however, we did not see any additional diagnostic accuracy for HCMV disease in the lung allograft by use of such an approach.
In the present study, histologically proven HCMV infection only became apparent within 4 weeks of stopping ganciclovir prophylaxis and was best detected by BAL sampling of the lung allograft. The recrudescence of HCMV disease after the end of antiviral prophylaxis has been previously described by others [15, 16] , as well by our own group [7] . Given the significant morbidity due to both direct and indirect effects of HCMV reactivation, the rationale for prolonged antiviral prophylaxis will need to be addressed in future studies. This rationale will need to be balanced against the potential for drug resistance [17] and increased health-care expenditure.
In conclusion, quantitative PCR analysis of HCMV load in BAL samples obtained for routine surveillance of LTRs and the application of a diagnostic threshold are associated with improved sensitivity and specificity for the histological detection of HCMV infection and offer the potential to monitor subclinical viral replication in the lung allograft. It is hoped that future longitudinal analysis of subclinical HCMV reactivation in BAL fluid and the associated specific antiviral immune re-sponses will lead to greater insights into the direct and indirect effects of HCMV on the lung allograft.
